Semax vs PT-141: Two Melanocortin-Related Peptides with Completely Different Applications
- Durham Peptides
- 10 hours ago
- 7 min read
Semax vs PT-141 melanocortin peptide comparison Durham Peptides Canada
Semax and PT-141 are two research peptides that share an unusual feature — both have origins related to the broader melanocortin peptide system. But despite this shared connection to melanocortin biology, the two compounds are studied for completely
different research applications and operate through largely distinct mechanisms. Semax is anchored in cognitive and neuroprotective research through BDNF modulation. PT-141 is anchored in melanocortin receptor pharmacology research, with mechanisms operating directly on the melanocortin receptor system that Semax appears to bypass.
This article provides a direct comparison between Semax and PT-141. The framing throughout is research literature observation — these are research peptides studied in published research, not therapeutic recommendations.
For the foundational coverage of each compound individually, see What Is Semax? A Research Overview of the ACTH(4-10) Analog Nootropic Peptide and What Is PT-141? A Research Overview of Bremelanotide and the Melanocortin Peptide Class.
The Quick Answer
Semax is a heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) — an analog of ACTH(4-10) with a Pro-Gly-Pro stability extension. Developed at the Russian Academy of Sciences. Studied primarily for BDNF modulation and neuroprotective mechanisms. Despite its ACTH origins, the research mechanisms appear to operate independently of melanocortin receptors.
PT-141 (bremelanotide) is a synthetic peptide based on the melanocortin pharmacophore. Studied primarily as a melanocortin receptor agonist with effects on the melanocortin signaling system. Has had pharmaceutical development pathway including FDA approval in pharmaceutical formulation for specific indications.
Both compounds share melanocortin-related ancestry, but they engage fundamentally different research applications:
Semax — cognitive and neuroprotective research through BDNF/neurotrophic factor mechanisms
PT-141 — melanocortin receptor pharmacology research
The Melanocortin Connection
Understanding why these two peptides are sometimes discussed together requires understanding the broader melanocortin peptide family.
ACTH (adrenocorticotropic hormone) is a 39-amino-acid peptide produced by the pituitary gland. ACTH's primary biological role is regulating adrenal steroid hormone production. But ACTH research in the 1970s and 1980s revealed that specific fragments of ACTH retained certain biological activities independent of the full hormone's adrenal effects.
α-MSH (alpha-melanocyte-stimulating hormone) is another peptide derived from the same precursor protein (POMC) as ACTH. α-MSH is studied for its role in melanocortin receptor pharmacology — particularly skin pigmentation and various other effects.
The melanocortin peptide family includes multiple peptides that engage melanocortin receptors. PT-141 is part of this family, designed as a melanocortin receptor agonist.
Where Semax fits. Semax is derived from ACTH(4-10) — amino acids 4-7 of ACTH are identical to amino acids 4-7 of α-MSH (both are derived from the same POMC precursor). However, Semax's research mechanisms appear to operate through BDNF modulation and neurotrophic factor pathways rather than primary melanocortin receptor activation. Semax has melanocortin-family origins but doesn't function as a melanocortin receptor agonist for its primary research effects.
Where PT-141 fits. PT-141 is designed specifically to engage melanocortin receptors. Its research mechanisms operate directly through the melanocortin receptor system that Semax bypasses.
Structural Comparison
Feature | Semax | PT-141 |
Length | 7 amino acids | 7 amino acids |
Source | ACTH(4-10) analog | Synthetic melanocortin pharmacophore |
Origin | Russian Academy of Sciences | Pharmaceutical development |
Target receptor | Operates through BDNF/neurotrophic pathways | Melanocortin receptors (specifically MC4R) |
Pharmaceutical history | Russian regulatory approval | FDA approval in pharmaceutical formulation |
Modifications | Pro-Gly-Pro C-terminal extension | Cyclic peptide structure |
Mechanism Comparison
The mechanisms diverge significantly despite the shared melanocortin family origins:
Semax mechanisms. The published research literature has investigated:
BDNF (Brain-Derived Neurotrophic Factor) modulation
TrkB receptor activation
Dopaminergic and serotonergic system effects
Neuroprotective effects in cerebral ischemia models
Independence from primary melanocortin receptor activation
Possible direct interaction with PEPT1 transporters in some cellular contexts
PT-141 mechanisms. The published research literature has investigated:
Melanocortin receptor agonist activity (particularly MC4R)
Direct engagement of the melanocortin receptor system
Specific effects related to melanocortin signaling
Pharmaceutical development pathway including approved indication
The difference matters: Semax is a melanocortin family-derived peptide that operates through BDNF/neurotrophic mechanisms outside primary melanocortin receptor signaling. PT-141 is a melanocortin family peptide that operates through direct melanocortin receptor activation. The shared family origin doesn't mean shared mechanism.
Research Application Comparison
The mechanism differences translate to entirely different research applications:
Semax research applications:
Cognitive function research
Neuroprotection studies (cerebral ischemia, neuronal damage)
BDNF and neurotrophic factor research
Stress response and anxiety research (overlapping with related Russian neuropeptide Selank)
Nootropic peptide research category
For broader nootropic context, see Nootropic Peptides Research Overview.
PT-141 research applications:
Melanocortin receptor pharmacology
Specific applications related to melanocortin signaling
Pharmaceutical development context (approved formulations)
Receptor pharmacology and selectivity research
For coverage of the broader melanocortin peptide category, see What Is PT-141? A Research Overview of Bremelanotide and the Melanocortin Peptide Class.
The application overlap is essentially zero. Researchers studying cognition use Semax. Researchers studying melanocortin receptor pharmacology use PT-141.
Regulatory Status Comparison
Both compounds have unusual regulatory profiles:
Semax. Has Russian pharmaceutical approval for specific indications under the Russian regulatory framework. Has not received approval in Canada, the US, or the EU. Operates under research-use-only framing for laboratory and research applications in Western markets.
PT-141. Has FDA approval in pharmaceutical formulation under specific brand names for specific therapeutic indications. Research-use peptide formulations are separate products in a separate regulatory category — not approved as research peptide products and operating under research-use-only framing.
For Canadian regulatory framework coverage, see Are Peptides Legal in Canada?.
Catalog Availability
The two compounds have different availability in the Durham Peptides catalog:
Semax 10mg. Available in the Durham Peptides catalog with full Janoshik third-party testing and Canadian-domestic shipping.
PT-141. Not currently in the Durham Peptides catalog. The PT-141 article exists as informational coverage of the broader melanocortin peptide research category. Researchers seeking PT-141 specifically need to evaluate other suppliers using the standard six-criteria framework — see 5 Things to Look for in a Canadian Peptide Supplier and Peptide Supplier Red Flags.
Decision Framework: When Each Applies
The choice between Semax and PT-141 isn't really a choice in most research contexts — they address different research questions:
Choose Semax research when:
Cognitive function research is the focus
Neuroprotection studies are the application
BDNF or neurotrophic factor mechanisms are central
Nootropic peptide research category is the framework
Russian Academy of Sciences research foundation supports the protocol
Choose PT-141 research when:
Melanocortin receptor pharmacology is the research focus
Direct melanocortin receptor agonism is needed
Specific applications related to melanocortin signaling are the application
Receptor selectivity research within the melanocortin family is the goal
Choose neither when:
Other research mechanism categories are more appropriate
The shared melanocortin family origin isn't actually relevant to the research question
Simpler peptide categories address the research more directly
Quality Considerations
For Semax specifically (since it's in the Durham Peptides catalog):
Manufactured via Solid-Phase Peptide Synthesis with synthetic amino acids
No animal-derived materials
Independent third-party testing by Janoshik Analytical
≥99% HPLC purity
Mass spectrometry identity confirmation
For PT-141 from any supplier, the same quality framework should apply — verifiable Janoshik COA, ≥99% HPLC purity, MS identity confirmation. The research-grade quality standard isn't supplier-specific.
For complete quality framework coverage, see How to Verify Peptide Quality and How to Read Mass Spectrometry Data on a Peptide COA.
Frequently Asked Questions
What's the connection between Semax and PT-141? Both have origins related to the broader melanocortin peptide family. ACTH (Semax's precursor) and α-MSH (related to PT-141's design) share the same POMC precursor protein. However, the compounds have completely different research mechanisms and applications.
Is Semax a melanocortin receptor agonist? No, despite its ACTH origins. Semax's primary research mechanisms appear to operate through BDNF and neurotrophic factor pathways rather than direct melanocortin receptor activation.
Is PT-141 a melanocortin receptor agonist? Yes. PT-141's research mechanisms center on direct engagement of the melanocortin receptor system, particularly MC4R.
Are they used for the same research applications? No. Semax is for cognitive and neuroprotective research. PT-141 is for melanocortin receptor pharmacology research. The applications don't overlap.
Does Durham Peptides sell PT-141? PT-141 is not currently in the Durham Peptides catalog. Semax 10mg is available. The PT-141 article is informational coverage of the broader melanocortin peptide category.
Why is Semax's mechanism different from its melanocortin family origins? The published research has documented Semax's effects operate primarily through BDNF modulation rather than melanocortin receptor activation. The Pro-Gly-Pro C-terminal extension and the specific structural design appear to redirect the compound's mechanism away from melanocortin receptor engagement.
Are both FDA-approved? PT-141 has FDA approval in pharmaceutical formulation for specific indications. Semax does not have FDA approval. Russian pharmaceutical approval exists for Semax but doesn't translate to FDA approval.
Are both vegan? Yes. Modern Semax is manufactured via SPPS with synthetic amino acids. PT-141 manufacturing also typically uses SPPS. See Vegan Peptides.
Can I substitute one for the other? No. They engage different mechanisms for different research applications. Substitution wouldn't address the same research question.
Which has more published research? Both have substantial published research bases in their respective application areas. Semax has decades of Russian Academy research plus growing Western literature. PT-141 has pharmaceutical development research plus the broader melanocortin pharmacology literature.
What other melanocortin family peptides exist? The broader family includes α-MSH, β-MSH, γ-MSH, ACTH, and various synthetic analogs. Each has different receptor selectivity profiles and research applications.
Why is the Russian pharmaceutical approval for Semax different from FDA approval? Different regulatory authorities operate different approval frameworks. Russian regulatory approval applies in Russia under the Russian framework. FDA approval applies in the US under the US framework. Health Canada approval applies in Canada under the Canadian framework. Approval in one jurisdiction doesn't translate to other jurisdictions. See Peptide Certifications Explained.
Final Thoughts
Semax and PT-141 share melanocortin family origins but address completely different research questions through largely distinct mechanisms. The shared family ancestry is an interesting biological connection but doesn't translate to shared research applications. Researchers studying cognition use Semax. Researchers studying melanocortin receptor pharmacology use PT-141.
For Canadian researchers, the practical takeaways:
Shared melanocortin family origins don't mean shared research mechanisms
Semax operates through BDNF and neurotrophic factor pathways for cognitive/neuroprotective research
PT-141 operates through direct melanocortin receptor engagement for receptor pharmacology research
The compounds aren't substitutes — they address different research questions
Semax is in the Durham Peptides catalog; PT-141 is informational coverage only
For continued reading, see What Is Semax?, What Is PT-141?, Nootropic Peptides Research Overview, Buy Semax in Canada, and The Complete Peptide Glossary.
Browse the complete Durham Peptides catalog at durhampeptides.ca/category/all-products. View all Janoshik-verified COAs at durhampeptides.ca/lab-results.
Selected Research References
Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an Analog of ACTH(4-10) with Cognitive Effects, Regulates BDNF and trkB Expression in the Rat Hippocampus. Brain Research. 2006;1117(1):54-60. https://pubmed.ncbi.nlm.nih.gov/16996037/
Pfaus JG, Shadiack A, Van Soest T, Tse M, Molinoff P. Selective Facilitation of Sexual Solicitation in the Female Rat by a Melanocortin Receptor Agonist. Proceedings of the National Academy of Sciences. 2004;101(27):10201-10204. https://pubmed.ncbi.nlm.nih.gov/15226502/
Eremin KO, Kudrin VS, Saransaari P, et al. Semax, an ACTH(4-10) Analogue with Nootropic Properties, Activates Dopaminergic and Serotoninergic Brain Systems in Rodents. Neurochemical Research. 2005;30(12):1493-1500. https://pubmed.ncbi.nlm.nih.gov/16362768/
Catania A, Gatti S, Colombo G, Lipton JM. Targeting Melanocortin Receptors as a Novel Strategy to Control Inflammation. Pharmacological Reviews. 2004;56(1):1-29. https://pubmed.ncbi.nlm.nih.gov/15001661/
Romanova GA, Silachev DN, Shakova FM, et al. Neuroprotective and Antiamnestic Effects of Semax during Experimental Ischemic Infarction. Bulletin of Experimental Biology and Medicine. 2006;142(6):663-666. https://pubmed.ncbi.nlm.nih.gov/17603667/
Cone RD. Studies on the Physiological Functions of the Melanocortin System. Endocrine Reviews. 2006;27(7):736-749. https://pubmed.ncbi.nlm.nih.gov/17077189/
All products sold by Durham Peptides are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease. This article is informational and does not constitute medical advice.
